Breaking News

Novavax Expands Large-Scale Global Manufacturing Capacity

Acquires Praha Vaccines in Czech Republic; annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen

By: Contract Pharma

Contract Pharma Staff

Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has acquired Praha Vaccines a.s., part of the Cyrus Poonawalla Group, for approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters